DBV Technologies S.A.: DBV Technologies to Participate in Upcoming ACAAI 2024 Congress
Châtillon, France, October 18, 2024 DBV Technologies to Participate in Upcoming ACAAI 2024 Congress DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage ...
DBV Technologies to Participate in Upcoming ACAAI 2024 Congress
Châtillon, France, October 18, 2024 DBV Technologies to Participate in Upcoming ACAAI 2024 Congress DBV Technologies ...
KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that five abstracts have been accepted for e-Poster ...
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings
ZUG, Switzerland, Oct. 16, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary ...
manilatimes4d
ICPO Foundation funded global "Radiopharmaceutical Trial Finder” developed by WARMTH and Ancora.ai
To address these challenges, WARMTH (World Association of Radiopharmaceutical and Molecular Therapy) and Ancora.ai with grant ...
MyChesCo on MSN5d
AstraZeneca’s AIRSUPRA Proven Effective in Reducing Severe Asthma Attacks
AstraZeneca has announced promising results from the BATURA Phase IIIb trial, showcasing the effectiveness of AIRSUPRA ...
Atlanta Journal-Constitution5d
What is urticaria? Harris’ medical report reveals she’s prone to this condition
Vice President Kamala Harris is in “excellent health” and “possesses the physical and mental resiliency” required to serve as president, her doctor said in a letter released Saturday that summarizes ...